Introduction: Second-generation Antipsychotics (SGAs) have become the treatment of choice over the typical antipsychotics as they provide excellent efficacy and fewer extrapyramidal symptoms. However, the compliance of the patients to SGAs is negatively affected by their ability to induce or aggravate metabolic syndrome, namely, weight gain, insulin resistance, and Type 2 Diabetes. The exact underlying mechanism of metabolic effects of SGAs is not fully elucidated and it is assumed to be at least partially due to their effect on central nervous system. However, whether SGAs have a direct effect on insulin action in the tissues is still to be elucidated. The effect of SGAs on body metabolism varies and we have chosen two drugs, Olanzapine and Aripiprazole, which are associated with high and low risk of metabolic side-effects, respectively.
Our research is focused on studying the effect of both SGAs on insulin resistance in human adipose tissue. Aside from lipid storage function, adipose tissue has been recognised, as an endocrine organ, producing hormones, such as adiponectin and leptin, indispensable for energy homeostasis. The set of experiments performed as a part of this study includes measuring the effect of Olanzapine and Aripiprazole on the lipolysis in human isolated adipocytes.
Methods:
Biopsies of subcutaneous adipose tissue (SAT) were collected from 6 patients (3 men, 3 women; age: 20-76 years; BMI: 20.9-34.5 kg/m2). Subjects were free of antidepressants or antipsychotics treatment. At the moment, only the effect of Olanzapine has been tested and measured, the experiments with Aripiprazole are in progress.
A 6% adipocyte suspension was incubated with olanzapine (0.004, 0.04, 0.1, 0.2, 2 and 20 µM) or aripiprazole (0.02, 0.2, 0.5, 1, 10 and 100 µM). This was followed by 10 minutes incubation with 4 concentrations of insulin (0.1 µU; 1.0 µU; 10 µU; 100 µU) and then incubated with 0.5 µM ß-adrenergic receptor agonist, Isopretenerol, for 1h 50 min. ß-adrenergic stimulation activates hormone-sensitive lipase (HSL) enzyme via cAMP-dependent pathway. HSL, in turn, hydrolyses tritriacylglycerol (TAG), diacylglycerol (DAG) or monoacylglycerol (MAG) molecules producing free fatty acids and glycerol. The supernatant was then collected and used for glycerol measurement.
Results: Short incubations of adipocytes with therapeutic concentrations of Olanzapine show no effect in lipolysis. The highest concentration of the drug hints at a reduced rate of lipolysis in adipocytes by more than 50% for each insulin concentration (p<0.0001) and in control conditions (p<0.01).
Conclusions: Therefore, it seems that short-term incubation of adipocytes with 20 µM Olanzapine reduces the rate of lipolysis, while the therapeutic concentrations do not seem to alter lipolysis in adipocytes.
Introduction: Alzheimer´s disease (AD) is the most common form of dementia. The alteration of several neurotransmitter systems has been reported. These alterations in the neurotransmission processes could be correlated with changes in the synthesis, storage or release of neurotransmitters.
Materials and Methods:
In this study we have used a triple transgenic murine model of AD (3xTg-AD). This animal model contains mutations in the gene encoding the amyloid precursor protein (βAPPSwe), presenilin-1 (PS1M146V) and tauP301L, which mimics the development of the disease on AD patients. We propose to study here the last steps of exocytosis in chromaffin cells of 3xTg-AD mice of different ages and their controls (WT) using the amperometric technique. Different ionic currents involved in the physiological release of catecholamines will be studied using the patch-clamp technique.
Results:
We have found significant changes in the exocytosis of catecholamines occurring in 3xTg-AD when compared with wildtype (WT) mice. These changes show an increase of the number of amperometric spikes during the development of the disease, as well as an increase in the quantal catecholamine content. Kinetic analysis of secretory spikes shows that as mice age amperometric spikes are faster in triggering and shorter in duration. However, the release of catecholamines is slower and longer in duration when comparing 3xTg-AD with WT mice.
Using the patch-clamp technique we found no changes in nicotinic currents, a decrease in sodium currents and an increase in potassium currents. Some alterations were also found in calcium currents.
Taken together, these findings suggest that throughout the development of 3xTg-AD mice and as Alzheimer's disease is established there are changes in chromaffin cell excitability, which causes an increase in neurotransmission.
Conclusion:
Although ageing caused some coincident alterations in the kinetics of exocytosis, there were also clear differences between WT and 3xTg-AD mice. These alterations could have an impact on the response that the organism offers in a stressful situation. Introduction: Epigenetic factors play an important role in psoriasis onset and development. There are different drugs available to treat moderate-to-severe psoriasis patients resistant to conventional systemic drugs. Although these drugs are safe and effective for moderate-to-severe psoriasis treatment, some patients do not show an adequate response to them. Therefore, it is necessary to find biomarkers that could predict patients´ response to these drugs. Objective: To analyse the association between nonconventional systemic drugs (ustekinumab, secukinumab, adalimumab, ixekizumab and apremilast) response and histone modifications in moderate-to-severe psoriasis patients.
Materials and methods:
Peripheral blood mononuclear cells (PBMCs) were isolated from psoriasis patients treated with nonconventional systemic drugs before and after the administration of these therapies. PBMCs obtained from healthy subjects have been used as controls. Afterwards, histones were extracted from PBMCs. Four different histone modifications (H3 and H4 acetylation, H3K4 and H3K27 methylation) were determined by Enzyme-Linked ImmunoSorbent Assay (ELISA). Data were analyzed by IBM SPSS v.23.
Results and conclusions:
Psoriasis patients presented reduced levels of acetylated H3 and H4 and increased H3K4 methylated levels compared to healthy controls. Global changes in any of the histone modifications analyzed were not observed in psoriasis patients between before and after treatment administration. Nevertheless, significant changes in methylated H3K27 were found between responders and non-responders to nonconventional systemic drugs. These results should be validated in large-scale studies before implementation in clinical practice.
Effects of olanzapine and aripiprazole on glucose uptake in healthy human subcutaneous adipocytes during short incubations. Introduction: Second-generation Antipsychotics (SGAs) are preferable pharmacological treatment for patients with Schizophrenia, mainly due to their efficacy and reduced risk of extrapyramidal effects when compared with first generation antipsychotics. However, there are metabolic side effects associated with the administration of SGAs, namely weight gain, dyslipidaemia and impaired glucose metabolism. Literature reports that even in the absence of antipsychotic treatment patients with Schizophrenia have a propensity to develop metabolic changes that can lead to cardiovascular diseases, insulin resistance, obesity and Type 2 Diabetes. Olanzapine and aripiprazole belong to SGAs and have been reported as drugs with the highest and the lowest risk of inducing metabolic changes, respectively. However, the pharmacological mechanisms underlying their metabolic side effects remain unclear and they will be the main focus of our study.
Cátia
Adipose tissue is not only specialized in storing lipids but it is also an endocrine organ that produces and secretes numerous biological active compounds that regulate metabolic homeostasis.
Our aim is to evaluate the effect of olanzapine and aripiprazole in the glucose uptake on human isolated adipocytes. Results: Short incubation of adipocytes with olanzapine or aripiprazole showed no effect on basal or insulin-stimulated glucose uptake, with the exception of supra-physiological concentrations of aripiprazole (10 and 100 μM) where we see a systematic decrease of basal and insulin-stimulated glucose uptake; 10 μM by ͌ 20-25% (p<0.05) and 100 μM by ͌ 60-70% (p<0.01).
Conclusions: Short-term treatment of isolated adipocytes with therapeutic doses of olanzapine or aripiprazole did not affect glucose uptake, suggesting no acute alteration in insulin activity. These data suggest that the plasma glucose increase seen in patients taking Olanzapine cannot be justified by acute alteration in insulin-signalling in adipocytes. Incubation with aripiprazole at 10 and 100 μM decreased the adipocyte glucose uptake but this might be justified by cell death, which will be explored in future experiments. , Cecilia Muñoz-Calleja Purpose: Dasatinib is a short-acting dual ABL/SRC family tyrosine kinase inhibitor (TKI), which is frequently used to treat chronic myeloid leukemia. Although very effective, dasatinib often displays severe adverse effects, including pleural effusions and increased risk of bleeding primarily in the gastrointestinal tract. The actual causes of these side effects are currently undetermined. We hypothesize that endothelial cells (ECs) that line the inner walls of blood vessels and control the traffic to the underlying tissues, might be involved.
Experimental design:
The effects of TKIs on ECs were studied by various assays, such as real-time cell impedance measurements, live-cell microscopy, wound healing, western blot and an in vivo model.
Results:
Dasatinib uniquely causes a profound, dose-dependent disorganization of the EC monolayers. Dasatinib promoted the disassembly of cell-cell contacts, altered cell-matrix contacts and further altered the wound healing. A key observation is that this effect is fully reversible after drug washout. In line with these in vitro observations, intraperitoneal administration of dasatinib to mice caused significant vascular leakage in the intestine. The underlying molecular mechanism of dasatinibinduced reorganization of the actin involves ROCK activation, which increases the amount of the phosphorylation of myosin light chain and consequently activates the non-muscle myosin II.
Conclusions:
Our data are consistent with a scenario in which dasatinib triggers a transient increase in vascular leakage that probably contributes to adverse effects such as bleeding diathesis and pleural effusions. 
Changes in the Gene

Introduction:
The immunomodulatory drug (IMiD) thalidomide and its structural analogs lenalidomide and pomalidomide are highly used to treat multiple myeloma (MM), however the molecular mechanism of IMiDs' action is not well-established. There before, we performed gene expression profiling analyses using microarray technologies to determine changes in genes involved in cellular biological pathways of MM induced by IMiDs in monotherapy.
Material and Methods:
We used MM1S cell line with concentrations of lenalidomide (1µM) and pomalidomide (100nM) in six-well plates for 1 and 5 days at 37 °C. After treatment, MM1S cells were evaluated by flow cytometry using Annexin-V and propidium iodide after selective labelling of plasma cells with CD38 and CD138 antibodies. The samples were analyzed using Affimetrix Gene-chip Expression Arrays. The absolute expression values for each probe were calculated using the MAS 5.0 software. The comparative analyzes were carried out using the Dchip program, the SAM algorithm, and the Ingenuity Pathway Analysis software. Expression changes were deemed significant if they were ±2-fold. Ingenuity Pathway Analysis was used to identify the most relevant biological mechanisms, pathways, and functional categories in the data set of genes selected by statistical analysis.
Results: After 1-day, in vitro treatment with lenalidomide (1µM), with 5-7% apoptosis, significantly deregulated 10 genes whereas treatment with pomalidomide (100nM), with 8-10% apoptosis, deregulated 19 genes. Among these genes, 6 genes were exclusively deregulated by lenalidomide, 15 were deregulated by pomalidomide, and 4 genes were regulated by both lenalidomide and pomalidomide. After 5-days, in vitro treatment with lenalidomide (1µM), with 20-22% apoptosis, significantly deregulated 39 genes whereas treatment with pomalidomide (100nM), with 25-27% apoptosis, deregulated 359 genes. Among these genes, 8 genes were exclusively deregulated by lenalidomide, 328 were deregulated by pomalidomide, and 31 genes were regulated by both lenalidomide and pomalidomide. These dysregulated genes are involved in the most relevant biological pathways for MM.
Conclusion:
We observed changes in the gene expression profile of MM cells after treatment with lenalidomide and pomalidomide, resulting pomalidomide with greater anti-MM effect. The under-expression of the MYB oncogeneregulator of transcription with an essential role in the control of the proliferation and differentiation of hematopoietic progenitor cells and their tumorigenesis-was commonly deregulated in both IMiDs lenalidomide and pomalidomide in monotherapy. Future studies may consider MYB as a new pharmacogenetic therapeutic target in MM. Cell damage was not mimicked by other cholinergic drugs and was unaffected by catalase, glutathione, N-acetyl-cysteine or melatonin. Cell death was elicited by apoptosis and necrosis. The apoptotic cell death elicited by OTI and PIN was prevent by cyclosporine A (CSA) a blocker of the mitochondrial transition pore and by Ac-LEHD-CHO an inhibitor of caspase-3 and caspase-9.
Conclusion: Data are compatible with the idea that OTI and PIN caused neuronal cell death by activating the intrinsic apoptotic pathway linked to mitochondria. These compounds may be used as new chemical tools to elicit neuronal apoptosis. We have studied whether other 3-substituted indoles also have a deleterious effect on the viability of the EBV+ BL cell lines Raji and BL60.2, and of CLL cells. Our results show that 3-substituted indoles with either carboxylic, methylcarboxylic, aminocarboxylic, cyanomethyl, carboxaldehide, dimethylaminomethyl, methoxymethyl or carboxamide groups failed to have any effect on the viability of the EBV+BL and CLL cells at concentrations up to 200 µM. Interestingly, not even 3-hydroxyethylindole and indole-2-methanol showed any cytotoxic effect, thus underlying the key role of the hydroxylmethyl group at 3 position for the anti-tumoral activity of I3C. It is noteworthy that indole-3-ol was cytotoxic in some of the tested cell lines. However, while I3C cytotoxicity was prevented by the caspases inhibitor zVAD-fmk, thus indicating that I3C induces apoptosis, zVAD-fmk failed to prevent indole-3-ol-induced cell death, thus suggesting that I3C and indol-3-ol kill by different mechanisms.
In addition, we have also demonstrated that 7-azaindole and 3-hydroxymethyl-7-azaindole lack of any deleterious effect on the viability of B cell malignancies under study. This result indicates that the replacement of C for N at 7-position of the indole ring abolishes its anti-tumor activity. Introduction: Amyotrophic lateral sclerosis (ALS) is characterized with a selective loss of motor neurons that cause paralysis and respiratory failure. Hyperexcitability and Ca2+-dependent glutamate excitotoxicity has been hypothesized to be involved in ALS pathogenesis. Exploring the chromaffin cell (CC) of SOD1 G93A mouse model of familiar ALS, we found that the fusion pore kinetics of exocytosis is slowed but with higher catecholamine quantal size when the disease is already established (Calvo-Gallardo et al., Am J Physiol Cell Physiol 2015;308:C1-C19). To go further in the study of these neurosecretion alterations, we investigate the exocytosis before the disease onset (30 days postnatal), and we focus in the study of mitochondrial ultrastructure and function as a crucial organelle involved in the process.
Material and Methods:
Mitochondrial ultrastructure was explored by transmission electron microscopy (TEM) and analyzed with ImageJ software. Luminometer was used to measure ATP levels in CC cultures with the commercial CellTiter-Glo® kit. Reactive oxygen species (ROS) production was monitored 30 minutes with the fluorescent dye H2DCFDA. Fusion pore kinetic was studied by amperometry, eliciting exocytosis by 1 minute acetylcholine stimulus.
Results: TEM showed that mitochondria from SOD1
G93A CCs have the following alterations with respect to wildtype CCs: i) more number and small sized; ii) increased mitochondrial intermembrane space; iii) lower number and swollen cristae. These ultrastructural changes suggesting mitochondrial fission and ultrastructure damage were accompanied by lower ATP production and a higher rate of ROS generation. However, we fail in observe such significant differences in the fusion pore kinetics.
Conclusion:
The described mitochondrial alterations shown an interesting non-motor neuron degeneration in this ALS model at presymptomatic stages. However, the kinetic of the exocytotic fusion pore have not been affected, contrary to the slowed secretion observed once the paralysis is already established. These results evidence that this mitochondrial alterations precede the functional changes linked to neurotransmitter release. In spite of having lower clinical relevance than in later stages, it could generate some clues about the initiation and progression of the disease. Our data consolidate the mitochondria as a potential target and the sympathetic-adrenal system affectation as an interesting new approach for ALS diagnosis. Introduction: Individualization of the therapeutic strategy for the oral antifungal voriconazole (VCZ) is highly important for treatment optimization. This is due to its narrow therapeutic range and its wide interpatient variability in serum concentrations, which are directly related to both VCZ efficacy and the occurrence of adverse drug reactions (ADRs). Part of this variability is explained by genetic variation in genes coding enzymes involved in the metabolic pathway of VCZ. To date, the European Clinical Pharmacogenetics Consortium and the US Food and Drug Administration include CYP2C19 as the only major PGx biomarker in their dosing guidelines and protocols; however, the effect of other genes might be important for VCZ dosing prediction. We developed an exploratory pharmacogenetics (PGx) study nested to a bioequivalence trial of two VCZ formulations of 200 mg to identify new biomarkers related to VCZ pharmacokinetics (PK) that could be included in clinical practice.
Prediction Models for Voriconazole Pharmacokinetics
Materials and Methods:
Forty-six healthy volunteers were included. Cmax, Tmax and AUC0-∞ were obtained from VCZ PK analysis and Cmax and AUC0-∞ were adjusted to dose/weight administered. Molecular analysis was performed for the selected SNPs among the CYP2C19, ABCB1, CYP3A4, CYP3A5, CYP2C9, POR, NR1I2, FMO3 genes using the custom SNParray genotyping platform PharmArray®. After molecular and PK analysis, we first designed a Clinical Practice VCZ AUC0-∞ prediction model based on CYP2C19 to be used as a reference model for comparison. We then performed a statistical analysis in three steps to design new prediction models by the incorporation of additional biomarkers.
Results: Due to the strong influence of CYP2C19 on VCZ AUC0∞ heterogeneity we propose that its major effect might be masking the influence of other metabolic enzymes and transporters in VCZ metabolism and that this influence could be unmasked by a stratification of the study population into CYP2C19 phenotypic subgroups. We here propose three different predictive models that improve the clinical practice model predictive rates by the incorporation of complementary biomarkers to CYP2C19.
Conclusion:
Due to the small sample size, further research is needed for cross-validation of the proposed models. However, the CYP2C9 gene was proposed as a consistent biomarker for VCZ AUC prediction in addition to the well-established CYP2C19 gene. 
Agranulocytosis after metamizole use
INTRODUCTION:
Metamizole is a non-narcotic analgesic/antipyretic widely used in some countries but prohibited in others due to suspected risk of agranulocytosis. The mechanism of this side effect has not been completely clarified, but it is generally accepted that it is immune-mediated. The lymphocyte transformation test (LTT) has been proposed as a diagnostic method to determine if a drug is the causal agent of an immune-mediated drug reaction. We present a case of drug-induced agranulocytosis in which Spanish Pharmacovigilance System probability algorithm of drug causality was applied and in vitro LTT was performed.
CLINICAL CASE:
A 30-year-old woman was admitted to our hospital with fever and severe weakness. Eighteen days before she had received knee surgery and was prescribed metamizole (MTZ) along with dexketoprofeno (DK) alterned every four hours. She was also on esomeprazole (ESO) and bemiparine treatment since the surgical procedure. Two days after the onset of treatment she presented fever up to 37.8ºC which was followed by increasing weakness in the next days. On day 6 after surgery, she was diagnosed tonsillitis and started therapy with amoxicillin-clavulanic. Body temperature values kept rising and weakness remained after amoxicillin-clavulanic therapy had been completed. Not showing any clinical improvement, she decided to come to our Hospital. Laboratory tests revealed severe neutropenia of 0.03×10e3/µL. Blood smear showed no alterations of the red cells, scarce neutrophils and no evidence of dysplasia. Haematological, infectious diseases and other alternative causes were excluded leading to drug suspicion. Possible causal drugs were discontinued and antibiotic prophylaxis in addition to filgastrim were started. The algorithm of Spanish pharmacovigilance system was conducted to MTZ, DK, ESO and bemiparine.
RESULTS:
Applying the algorithm, MTZ, DK and ESO obtained 4 points, which implies "possible causality". Bemiparine pointed a "conditional causality" (2 points), and was consequently excluded. After drug withdrawal of (MTZ, DK, ESO) and filgastrim therapy, she showed clinical and analytical improvement and was discharged from Hospital. We performed LTT to the remaining suspected drugs. The test had a positive result for MTZ, and was negative for DK and ESO. A recommendation was made to the patient and stated on clinical records not to rechallenge to metamizole or other pyrazolones again.
CONCLUSIONS: This is to our concern the first case of agranulocytosis by metamizole in which LTT has been performed. The positive result elucidated metamizole as causal agent and supports the hypothesis of immunological mechanism for this adverse reaction. The establishment of a pharmacogenetics unit with the intention of facilitating the integration of pharmacogenetic testing into clinical practice is important to personalise treatments and clinical recommendations and to carry out pre-emptive genotyping in risk populations. In our Clinical Pharmacogenetics Unit at La Paz University Hospital we classified pharmacogenetics tests into three groups. One of these groups are drugs with well-known evidence but without a well-defined protocol. In these cases, we evaluate a specific therapeutic problem and determine whether the pharmacogenetics test is recommended. We presented the case of a patient with suspected drug-induced parkinsonism (DIP) related with antipsychotic treatment.
Material and Methods:
DIP is the most common movement disorder induced by antipsychotics and reduces quality of life favouring non-compliance of treatments in patients with psychotic disorders with risk of morbidity and mortality. We evaluated a patient being treated with several drugs (sertraline, paroxetine, risperidone, quetiapine, zuclopenthixol, haloperidol and aripiprazole) who had developed parkinsonism one year earlier. Information about the pharmacogenetic testing variants and their impact on drug response was gathered mostly from the variant and clinical annotations in PharmGKB. We analysed single nucleotide polymorphism (SNP) associated with the metabolism and response of these drugs. We selected CYP2D6 and CYP2C19 as the most important biomarkers involved (all drugs have metabolism by CYP2D6, except sertraline which has metabolism mainly by CYP2C19). Pharmacogenetic test was performed and 21 SNP were analysed with OpenArray technology (PharmArray®).
Results:
Our patient presented the genotype CYP2C19*1/*17 (Rapid Metabolizer) and CYP2D6*4/*41 (Intermediate Metabolizer). So, sertraline metabolism is increased and the metabolism of the other antipsychotic drugs are reduced and the higher plasma concentrations may increase the probability of side effects, among them DIP.
Conclusions:
These results could explain the higher risk of DIP observed in our patient due to the pharmacokinetic interaction at the level of CYP450. We are aware of the limitations of the CYP2D6 technique analysis but in the case of our patient it is important to consider these results in the evaluation of clinical symptoms due to the severity of the side effects of this type in therapeutic efficacy and the optimal treatment of antipsychotic disorders. In addition, it is important to point out the implementation of clinical pharmacogenetics programs in the clinical practice to carry out individualization of clinical recommendations and pre-emptive genotyping in risk populations. Methods: Female preterm, born at 34 weeks in a gemelar delivery, with a policystic multicompartimental lymphatic malformation with cervical airway compromise, required intubation. Sirolimus dosing in neonates is not clear, but therapy with 0.8mg/m2 every 12 hours was started the day after the born. After five days the through concentration was supratherapeutic (>90ng/ml), being the goal trough 5-15ng/ml. The dose was decreased to 0.1mg/kg once daily, but supratherapeutic levels persisted for three more days. Sirolimus was discontinued to avoid toxicity. Moreover, the pharmacogenetics study was carried out in order to pick up some mutation which could explain the supratherapeutic levels.
KV1.3 channel inhibition by indolic compounds in
Results: Sirolimus levels started to go down the fourth day after the suspension. Ten days after the last dose, the through had decreased until 9.21ng/ml. Estimated sirolimus half-life, calculated with the last concentration points after discontinuation, was 55 hours, which is similar to the half-life observed previously. After that, sirolimus 0,05mg/kg/day was restarted, remaining in the within the therapeutic range. The genotype determination of CYP3A4 (rs55785340, rs4646438, rs2740574, rs35599367, rs28371759, rs138105638, rs67666821), CYP3A5 (rs776746, rs55965422, rs10264272, rs41303343, rs41279854), CYP3A7 (rs45465393, rs11568824, rs45494802, rs45575938, rs45467892, rs11568825, rs11568826, rs45446698, rs55798860, rs28451617, rs2257401, rs779179631) and CYP2C8 (rs11572080, rs10509681, rs1058930, rs11572103) was performed. It did not show any mutation. Sirolimus is a substrate of CYP3A4, whose expression is very low in neonates, instead they express CYP3A7. Maturation of hepatic enzyme composition occurs over the first 6 months of life, with rapid changes in the first 3-6 weeks. Some studies have modelled the pharmacokinetic of sirolimus in infants and children, demonstrating significant variability attributed to body size and organ maturation processes, including bioavailability and hepatic metabolism.
Conclusion:
The cause of the supratherapeutic sirolimus levels was probably the immaturity, as the genetic test showed a normal metabolizer genotype. Important uncertainty exists about the appropriate dosage and schedule in the first postnatal days/weeks. More studies are needed to clarify these questions and others like the efficacy and safety.
Cyclosporine-induced lymphoproliferative disorder in toxic epidermal necrolysis (net): a case report. Introduction: Alzheimer's disease (AD) is a progressive neurological disease that causes a progressive memory loss. Main histopathological hallmarks of AD are senile plaques, and neurofibrillary tangles, generated by aggregation of the microtubule associated protein tau. In addition to these pathological characteristics, there are other alterations, such as oxidative stress or loss of cholinergic transmission, among many others. One of the most promising approaches in AD treatment is to inhibit neurofibrillary degeneration produced by an abnormal tau hyperphosphorylation. In this sense, serine/threonine phosphoprotein phosphatase 2A (PP2A) is the major phosphatase in brain that accounts for over 70% of tau dephosphorylation. It has been shown that PP2A activity is significantly decreased in postmortem AD brains, partly due to the increase of endogenous inhibitors that bind the PP2A catalytic subunit C.
Hypothesis:
Okadaic acid (OA) is a natural toxin capable of inhibiting PP2A, leading to tau hyperphosphorylation. Our working hypothesis is based on antagonizing the inhibitory effects of OA on PP2A by designing analogues of OA, capable to bind to PP2A but without exerting inhibition, and thus preventing the attachment of endogenous inhibitors.
Material y Methods:
The compounds synthesized, analogues to C19-C27 OA fragment, have been pharmacologically studied, evaluating them in several in vitro models of AD, such as: tau hyperphosphorylation induced by OA, oxidative stress caused by the toxic cocktail rotenone and oligomycin A or the glutamate induced excitotoxicity, all of them by the MTT method. Furthermore, we have measured the cellular phosphatase activity by the pNPP method. In order to carry out these objectives, we have used SH-SY5Y neuroblastoma cells and rat embryonic cortical neurons. Finally, we confirm our theory by docking studies.
Results and conclusions:
Our molecules are not toxic in SH-SY5Y cells or in cortical neurons, and they are capable of reducing the neurotoxicity induced by OA. Some of them also showed good profile in the cell stress model induced by R/O A in SH-SY5Y cells, and in the glutamate-induced excitotoxicity in cortical neurons. The new compounds maintained the serine/ threonine phosphatase activity, depressed by the action of two PP2A inhibitors: OA and citostatin. Molecular docking studies indicated that compound ITH12680 is capable of binding to PP2A similarly to OA, but it does not interact with the catalytic site, thus confirming our starting hypothesis. Taking into account these results, we conclude that our compounds have potential indication for the treatment of neurodegenerative diseases based on the maintenance of PP2A activity, which prevents tau hyperphosphorylation.
Introduction: Schizophrenia (SCZ) is a chronic brain disorder with symptoms of hallucinations, delusions, disturbed behavior and emotional and cognitive impairment. These symptoms are managed by administration of antipsychotic drugs (APDs), either as a single APD or a combination of different APDs depending on the individual. It is always recommended to take a maintenance dose of APD even after the reduction of SCZ symptoms which makes it a lifelong treatment. APD treatment is currently known to be the only effective treatment against SCZ. However, they are observed to trigger metabolic dysfunctions such as insulin resistance, obesity, coronary heart diseases and dyslipedemia in SCZ patients at the later stage during APD treatment. The main aim of the project is to identify a biomarker signature that could be detected in blood to diagnose the metabolic dysfunction due to APD administration at an early stage. The talk will provide an insight into omic approaches for biomarker discovery and a worked example of these approaches using relevant existing data sets from public repositories.
Materials and Methods:
The public repository Array Express (AE) (https://www.ebi.ac.uk/arrayexpress/) was used to shortlist the datasets from transcriptomic studies of primary human hepatocytes (PHH) that has been treated with any antipsychotic drug. R studio was used to process the data and shortlist genes that had a minimum fold change of 2. Bioinfominer online tool (https://bioinfominer.com/) was used for Gene ontology enrichment analysis.
Results and conclusion:
We found a microarray dataset of PHH that has been treated with Chlorpromazine (APD) from AE (AE id: E-MTAB-1747). The deregulated gene list from PHH that were treated with CPZ was significantly grouped under inflammatory and immune response from the gene ontology term enrichment analysis. Since the gene products of the inflammatory/immune response are mostly secreted, they are likely to be detected in blood which makes them potential biomarker candidates. However, these candidates were identified from PHH isolated from a single donor, so more work would be required to confirm them as valid biomarkers. Despite that caveat, the gene list can be considered as a useful reference list for future experiments. Introduction: Glioblastoma multiforme (GBM) constitutes the most frequent and aggressive primary brain tumor in adults. Even vast efforts have been made to develop effective treatments, including the combination of surgery, chemotherapy, and radiotherapy; the prognosis for the patients is extremely poor, with mean survival of about 14 months. Therefore, there is still an urgent need for novel and effective therapies for treating these tumors. On this issue, natural product-based molecules represent interesting therapeutic alternatives. Hispanolone derivatives have been shown to induce apoptosis in several human cancer cells. Nevertheless, the activity of these compounds against glioblastoma cells remains unclear. In the present study, we aimed to investigate the effects of a hispanolone derivative, α-hispanolol, on proliferation as well as on the migration and invasion of human glioblastoma cells.
Material y Methods:
Cytotoxicity of α-hispanolol was determined against glioblastoma cancer cells, using the MTT assay.
Flow cytometry was performed to analyze the changes in cell cycle and apoptotic effect, if any. Cells were also studied for their wound healing and invasive potential as well as for Western blotting of apoptotic genes.
Results:
Our results show that α-hispanolol induced cell morphological changes and decreased the cell viability of U87 and U373 cells in a dose-and time-dependent manner. This inhibitory effect was found to be linked to arrest of cell cycle at the G0/G1 phase, along with induction of apoptosis and accumulation in the sub-G1 phase. Moreover, α-hispanolol also induced caspases activities and increased the pro-apoptotic protein (Bax and Bid), and inhibited the anti-apoptotic proteins (Bcl-2 and Bcl-xl) in GBM cells. In addition, α-hispanolol displayed an inhibitory effect on the migration and invasion of glioma cells by inhibiting the expression and activity of MMPs.
Conclusion:
Our findings suggest that α-hispanolol may have therapeutic potential for the treatment of glioblastomas.
